AnaptysBio (ANAB) Stock Looks Undervalued Even After A 273% Rise

AnaptysBio has delivered very strong gains over the past few years, which puts a spotlight on whether the current share price is properly supported by its earnings profile. After such a run, the key issue for you is whether the recent market enthusiasm lines up with what the business is actually earning today. Over the past 3 years the stock has climbed 273.3%, which now raises the question of how much of that rise is backed by sustainable earnings power. The business model relies heavily on...